 Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Long-term risk assessment of combined radiotherapy after breast-conserving surgery for ductal carcinoma in situ of the breast

Br J Cancer: Long-term risk assessment of combined radiotherapy after breast-conserving surgery for ductal carcinoma in situ of the breast

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

all strong acids

thc breast milk

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since the introduction of population-based mammography for breast cancer screening in the 1990s, ductal carcinoma in situ (DCIS) has accounted for approximately 15% of all newly diagnosed breast cancers

Breast cancer screening DCIS is considered to be a non-obligate precursor of invasive breast cancer (IBC), which is composed of tumor epithelial cells of the breast duct system

Due to the invasive potential of DCIS, patients usually undergo mastectomy or breast-conserving surgery (BCS) for IBC treatment, accompanied by radiotherapy (RT) to the entire breast

The study aims to evaluate the impact of DCIS treatment on the 20-year risk of ipsilateral DCIS (iDCIS) and ipsilateral invasive breast cancer (iIBC) in a population-based cohort

The cohort included all women who were diagnosed with DCIS in the Netherlands between 1989 and 2004 and were followed up until 2017

diagnosis

Cumulative incidence of iDCIS and iIBC according to menstrual period and age

The results showed that the 20-year cumulative incidence of any ipsilateral breast event after BCS was 30.

Compared with BCS+RT treatment, female patients receiving BCS treatment have a higher risk of iDCIS and iIBC within 5 years after diagnosis

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.